NRAS and melanoma: In this study, the difference observed under inhibition of PD-1 was attributed to higher levels of PD-L1 detected in NRAS-mutant tumors, even though previous reports had found no significant differences in PD-L1 expression in human melanoma cell lines of different genotypes (Atefi et al., 2014).